We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Human Diagnostics Announces the Acquisition of LABiTec

By LabMedica International staff writers
Posted on 10 Mar 2014
Human Diagnostics (HUMAN Gesellschaft für Biochemica and Diagnostica GmbH; Wiesbaden, Germany), a global provider of diagnostic products, clinical analyzers, reagents, and medical laboratory supplies, has acquired all shares of LABiTec (LAbor BioMedical Technologies GmbH; Ahrensburg, Germany), a global supplier of systems for blood coagulation and aggregation diagnostics. More...
The purchase price was not disclosed

LABiTec specializes in the development, manufacture, and marketing of analyzers for coagulation diagnostics and platelet function testing (aggregation), with over 10,000 systems installed among 56 countries. LABiTec becoming part of the HUMAN group strengthens HUMAN’s technological expertise for the in-house development and the production of laboratory diagnostic analysis systems in the area of coagulation. The step also enhances its product range in the near-term with an automatic coagulation analyzer. LABiTec will continue its presence as an independent company in world market.

HUMAN's Managing Director, Ralph Neuberger, said, "We are very pleased to welcome LABiTec to our group. The excellent reputation of the brand LABiTec, technologically superior products, and the outstanding development competence are important pillars upon which, together, we can further expand our international market position." Hartmut Kehrbach, former owner of LABiTec who will stay on as a consultant, added, "For me, HUMAN, with its impressive global presence, is the ideal partner for LABiTec. I am convinced that LABiTec can make a significant contribution to the continued growth of the HUMAN group."

HUMAN was advised in this transaction by the consultancy CFP BioConnect AG, which specializes in the life sciences sector and is part of the Corporate Finance Partners Group in Frankfurt. Legal consulting was provided by the law firm Taylor Wessing, Hamburg.

Related Links:

HUMAN
LABiTec



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Aspiration System
VACUSAFE
New
Immunofluorescence Analyzer
IFA System
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.